Slingshot members are tracking this event:

Target enrollment of 500 patients in AR101 PALISADE Phase 2 studies is on track to complete in the second half of this year, and we expect top-line data in the second half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AIMT Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Palisade, Peanut-allergic Individuals